Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health

Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health

Abstract Background Who benefits from the commercial biomedical research and development (R&D)? Patients-consumers and investors-shareholders have traditionally been viewed as two distinct groups with conflicting interests: shareholders seek maximum profits, patients - maximum clinical benefit....

Full description

Bibliographic Details
Main Author: Slavek Roller
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Globalization and Health
Subjects:
Pharmaceuticals
Drug development
Access to medicines
R&D investment
Corporate governance
Online Access:http://link.springer.com/article/10.1186/s12992-019-0490-x

Internet

http://link.springer.com/article/10.1186/s12992-019-0490-x

Similar Items